Sep 6, 2025, 14:04
Chokri Ben Lamine – VTE Prophylaxis in Pregnancy (ASH 2018 Guidelines)
Dr. Chokri Ben Lamine, Adult Hematology and Stem Cell Transplantation Assistant Consultant at Oncology Center of Excellence at King Faisal Specialist Hospital and Research Center, shared an insightful post on X:
“ASH 2018 VTE Prophylaxis in Pregnancy
Prior VTE
- Unprovoked / hormone-related → Antepartum: Yes, Postpartum: Yes
- Provoked (transient risk only) → Antepartum: No, Postpartum: Yes
Thrombophilia
Heterozygous FVL / Prothrombin G20210A
- No FHx → Antepartum: No, Postpartum: No
- +FHx → Antepartum: No, Postpartum: Yes
Protein C deficiency
- No FHx → Antepartum: No, Postpartum: No
- +FHx → Antepartum: No, Postpartum: Yes
Protein S deficiency
- No FHx → Antepartum: No, Postpartum: No
- +FHx → Antepartum: No, Postpartum: Yes
Compound heterozygosity
- No FHx → Antepartum: No, Postpartum: Yes
- +FHx → Antepartum: Yes, Postpartum: Yes
Homozygous FVL
- No FHx → Antepartum: No, Postpartum: Yes
- +FHx → Antepartum: Yes, Postpartum: Yes
Homozgous Prothrombin
- No FHx → Antepartum: No, Postpartum: No
- +FHx → Panel unable to recommend, Postpartum: Yes
Antithrombin deficiency
- No FHx → Antepartum: No, Postpartum: No
- +FHx → Antepartum: No, Postpartum: Yes
Other risks
- No or 1 risk factor → Antepartum: No, Postpartum: Yes
- Assisted reproduction →
-Without ovarian hyperstimulation / high-risk → Antepartum: No
-With OHSS or high-risk thrombophilia → Antepartum: Yes, Postpartum: Yes
Pearls for exams
- Postpartum period = highest risk → most recommendations support prophylaxis here
- Antepartum prophylaxis reserved for high-risk thrombophilia with FHx or prior unprovoked/hormonal VTE
- LMWH = preferred agent
Reference: ASH-SAP 9th Ed, Table 3-2”

More series on VTE featured in Hemostasis Today.
-
Jan 25, 2026, 15:57Céline Chapelle Shares Clinical Predictors From the API-CAT Trial
-
Jan 25, 2026, 15:42Francesco Lo Monaco on Heart Disease Starting Quiet While Your Labs Speak First
-
Jan 25, 2026, 15:33Wilfried Dinh: Why Heart Patients Still Have Events Despite ”Optimal” Cardiovascular Therapy
-
Jan 25, 2026, 15:25Muhammad Ibrahim on Efficacy and Safety of Extended DOACs Use in VTE
-
Jan 25, 2026, 15:08Tushar Pandey on Managing Thrombotic Thrombocytopenic Purpura
-
Jan 25, 2026, 14:55Carolina Contreras Cuevas Shares a Nationwide Study on VTE in PAD
-
Jan 25, 2026, 14:40Jeannie Devereaux Links PRP and Physical Therapy
-
Jan 25, 2026, 14:25Heghine Khachatryan on Anticoagulation After AFib Ablation: New Evidence from NEJM
-
Jan 25, 2026, 12:42Lale Tokgözoğlu on Cardiovascular Risk Factors in Women
